Physician profile
Benjamin Dratch
NPI 1023371762
$2,295.15
in general payments reported to CMS, 2019-2025
18 companies · $679 in 2025
The $679 reported for 2025 was more than what 79% of Family Medicine providers received nationally (typical 2025 total: $153).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2023: $354 · 2024: $1,261 · 2025: $679.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $2,295.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $2,295.15 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Novo Nordisk INC | $399.35 | 2023-2025 | Ozempic, Rybelsus, Wegovy |
| Astrazeneca Pharmaceuticals Lp | $339.54 | 2023-2025 | Farxiga, Airsupra, Breztri |
| Merck Sharp & Dohme LLC | $329.91 | 2023-2025 | Verquvo, Lagevrio, Gardasil 9 |
| Lilly USA, LLC | $254.58 | 2023-2025 | Mounjaro, Zepbound, Jardiance |
| Exact Sciences Corporation | $182.45 | 2023-2025 | Cologuard Collection Kit, The Cologuard Plus Collection Kit |
| Pfizer INC. | $155.49 | 2023-2025 | |
| Astellas Pharma US INC | $111.90 | 2023-2025 | Veozah, Myrbetriq |
| Abbvie INC. | $108.52 | 2023-2025 | Qulipta, Ubrelvy |
| Bayer Healthcare Pharmaceuticals INC. | $95.77 | 2023-2024 | |
| Kowa Pharmaceuticals America, INC. | $80.66 | 2024-2025 | Zoryve |
| Amgen INC. | $74.88 | 2023-2025 | Otezla, Repatha, Otezla |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $50.00 | 2024 | Xifaxan |
| Takeda Pharmaceuticals U.S.A., INC. | $32.71 | 2023-2024 | Trintellix |
| Esperion Therapeutics, INC. | $21.94 | 2023 | Nexletol |
| Glaxosmithkline, LLC. | $15.91 | 2024 | Arexvy |
Show all 18 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Boehringer Ingelheim Pharmaceuticals, INC. | $14.75 | 2024 | Jardiance |
| Paratek Pharmaceuticals, INC. | $13.46 | 2024 | Nuzyra |
| Novartis Pharmaceuticals Corporation | $13.33 | 2024 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Benjamin Dratch listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.